Trial results for the "Antiretroviral Improvement Among Medicaid Enrollees" (AIMS) study in Human Immunodeficiency Virus (HIV) were posted on 2025-10-21. The study was terminated with an enrollment of 4 participants.
Background
Human Immunodeficiency Virus (HIV) infection requires consistent adherence to antiretroviral therapy (ART) to achieve viral suppression, prevent disease progression, and reduce transmission. Despite the availability of effective treatments, challenges with ART adherence persist, particularly among vulnerable populations such as Medicaid enrollees. Programs designed to improve medication adherence and prescription filling rates are crucial for optimizing health outcomes for people living with HIV. This study aimed to evaluate whether a new program could positively impact ART prescription filling and overall health in this specific demographic.
Trial design
This study, designated as Phase NA, was terminated with an enrollment of 4 participants. It investigated conditions related to Human Immunodeficiency Virus. The trial aimed to evaluate a new program, referred to as the AIMS program, against usual care. The intervention type involved a program designed to affect how often antiretroviral therapy (ART) prescriptions are filled and to improve the health of people living with HIV. Participants were assigned to either a "Usual Care" group or an "AIMS program - patient" group.
Key results
The trial reported several key measurements:
- For "Number and Percentage of Participants Virally Suppressed":
- The "Usual Care" group had 0 participants.
- The "AIMS program - patient" group had 0 participants.
- For "Number and Percentage of Participants Reinitiating Late Antiretroviral Therapy (ART) Prescription":
- The "Usual Care" group had 0 participants.
- The "AIMS program - patient" group had 4 participants.
- For "Antiretroviral Therapy (ART) Adherence":
- The "Usual Care" group had 0 participants.
- The "AIMS program - patient" group had 3 participants.
What this means
The termination of the "Antiretroviral Improvement Among Medicaid Enrollees" (AIMS) study with a very limited enrollment of 4 participants restricts the ability to draw definitive conclusions. While the results indicate that 4 participants in the AIMS program group reinitiated late ART prescriptions and 3 showed ART adherence, no participants in either group achieved viral suppression. The small sample size and early termination mean that the program's effectiveness in improving ART adherence, prescription filling, or viral suppression in the target population could not be adequately assessed.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05477485, titled "Antiretroviral Improvement Among Medicaid Enrollees", were posted on 2025-10-21 on clinicaltrials.gov.